BACKGROUND: Long-term results of Roux-en-Y gastric bypass (RYGB) are nonexistent in the veterans affairs (VA) population. We compare excess weight loss (EWL) success and medical comorbidity changes between the VA and non-VA population after RYGB. METHODS: Retrospective review of consecutive subjects undergoing RYGB from 1997 to 2002 at the Los Angeles VA. Weight and comorbidity data were collected every 6 and 12 months, respectively. RESULTS: Fifty-nine subjects were included; 54%, 58%, 46.8%, and 44.1% of subjects achieved EWL >50% at years 1 to 4. Hypertension resolved in 23%, 30%, and 32% at months 12 to 36. Obstructive sleep apnea resolved in 37%, 48%, 48%, 44%, and 60% at months 12 to 60. Diabetes mellitus resolved in 86%, 84%, 79%, and 80% at months 12 to 48. Improvements in the lipid panel were observed by month 12 and maintained thereafter. CONCLUSIONS: EWL and proportion of subjects with resolved hypertension and obstructive sleep apnea are inferior to the non-VA population. Nevertheless, improvements in measures of success are maintained in the VA population.
BACKGROUND: Long-term results of Roux-en-Y gastric bypass (RYGB) are nonexistent in the veterans affairs (VA) population. We compare excess weight loss (EWL) success and medical comorbidity changes between the VA and non-VA population after RYGB. METHODS: Retrospective review of consecutive subjects undergoing RYGB from 1997 to 2002 at the Los Angeles VA. Weight and comorbidity data were collected every 6 and 12 months, respectively. RESULTS: Fifty-nine subjects were included; 54%, 58%, 46.8%, and 44.1% of subjects achieved EWL >50% at years 1 to 4. Hypertension resolved in 23%, 30%, and 32% at months 12 to 36. Obstructive sleep apnea resolved in 37%, 48%, 48%, 44%, and 60% at months 12 to 60. Diabetes mellitus resolved in 86%, 84%, 79%, and 80% at months 12 to 48. Improvements in the lipid panel were observed by month 12 and maintained thereafter. CONCLUSIONS: EWL and proportion of subjects with resolved hypertension and obstructive sleep apnea are inferior to the non-VA population. Nevertheless, improvements in measures of success are maintained in the VA population.
Authors: Y Van Nieuwenhove; W Ceelen; A Stockman; H Vanommeslaeghe; E Snoeck; K Van Renterghem; D Van de Putte; P Pattyn Journal: Obes Surg Date: 2011-05 Impact factor: 4.129
Authors: Marie-Pierre St-Onge; Michael A Grandner; Devin Brown; Molly B Conroy; Girardin Jean-Louis; Michael Coons; Deepak L Bhatt Journal: Circulation Date: 2016-09-19 Impact factor: 29.690
Authors: Nancy Puzziferri; Thomas B Roshek; Helen G Mayo; Ryan Gallagher; Steven H Belle; Edward H Livingston Journal: JAMA Date: 2014-09-03 Impact factor: 56.272
Authors: Jodi B Segal; Jeanne M Clark; Andrew D Shore; Francesca Dominici; Thomas Magnuson; Thomas M Richards; Jonathan P Weiner; Eric B Bass; Albert W Wu; Martin A Makary Journal: Obes Surg Date: 2009-12 Impact factor: 4.129
Authors: Tammy L Kindel; Stephanie M Yoder; Randy J Seeley; David A D'Alessio; Patrick Tso Journal: J Gastrointest Surg Date: 2009-05-12 Impact factor: 3.452
Authors: H E Bays; B Laferrère; J Dixon; L Aronne; J M González-Campoy; C Apovian; B M Wolfe Journal: Int J Clin Pract Date: 2009-09 Impact factor: 2.503